NNC0519-0130
Sources
registry, as of 2026-03-11Stale
https://clinicaltrials.gov/study/NCT06717698
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease. Overall status RECRUITING. Phases PHASE2. Lead sponsor Novo Nordisk A/S. Enrollment 465. Conditions Chronic Kidney Disease. The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes, living with overweight or obesity. The participant
ClinicalTrials.gov NCT06717698 protocol and results modules
registry, as of 2025-12-31Stale
https://clinicaltrials.gov/study/NCT05363774
A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.. Overall status COMPLETED. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 161. Conditions Healthy Volunteers (Diabetes Mellitus, Type 2). NNC0519-0130 is a new medicine which may possibly help participants with type 2 diabetes, as it is expected to lower elevated sugar levels in the blood. The medicine may also lower the appetite. This could help reducing overweight which is often present in participants with type
ClinicalTrials.gov NCT05363774 protocol and results modules
registry, as of 2026-04-03Stale
https://clinicaltrials.gov/study/NCT06718998
A Research Study Comparing Different Ways of Increasing the Dose of NNC0519-0130 in Participants With Overweight or Obesity. Overall status COMPLETED. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 134. Conditions Obesity. Novo Nordisk is developing a new study medicine NNC0519-0130 to improve the treatment options for people living with type 2 diabetes and people with excess body weight. This study will look at the safety and tolerability of NNC0519-0130. The purpose of this study is to investigat
ClinicalTrials.gov NCT06718998 protocol and results modules
registry, as of 2025-12-31Stale
https://clinicaltrials.gov/study/NCT06567041
A Research Study of How Safe a New Medicine Called NNC0519 0130 is and to Test Its Effect in People Living With Excess Body Weight With or Without Type 2 Diabetes. Overall status COMPLETED. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 82. Conditions Diabetes Mellitus, Type 2; Obesity. A new study medicine called NNC0519-0130 to improve treatment options for people living with excess body weight, with or without type 2 diabetes. The purpose of the study is to investigate potential side effects and blood levels of NNC0519-0130, as well as changes in body weight,
ClinicalTrials.gov NCT06567041 protocol and results modules
registry, as of 2025-11-25Stale
https://clinicaltrials.gov/study/NCT06642571
A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the Medicine. Overall status COMPLETED. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 46. Conditions Obesity. This study will look into a new study medicine called NNC0519-0130 to improve the treatment option for people living with excess body weight or type 2 diabetes or both. The purpose of this study is to compare the amount of NNC0519-0130 in the blood of participants who have excess
ClinicalTrials.gov NCT06642571 protocol and results modules
registry, as of 2026-03-31Stale
https://clinicaltrials.gov/study/NCT07004322
A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body Weight. Overall status COMPLETED. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 20. Conditions Diabetes Mellitus, Type 2; Obesity. Novo Nordisk is developing a new study medicine NNC0519-0130 to improve the treatment options for people living with type 2 diabetes and excess body weight. In this study, the concentration of NNC0519-0130 in the blood will be measured and its safety will be evaluated. The partic
ClinicalTrials.gov NCT07004322 protocol and results modules